drugset / Trial / NCT00979004

A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients

NCT00979004

Phase 2 Terminated 13 enrolled Pfizer
RandomizedCrossoverSingle-blindTreatment

Summary

Subjects with epilepsy with a documented photoparoxysmal response to intermittent photic stimulation (IPS) will participate. Four subjects will be enrolled at each dose level and will receive a single dose of placebo and a single dose of ICA-105665 during the study, each followed by intermittent photic stimulation. The effects of ICA-105665 on the photoparoxysmal electroencephalography (EEG) response of each group will be reviewed before the dose is selected for each subsequent group of subjects.

Timeline

Start
2009-09
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ICA-105665 Unknown 50 mg Oral
Subject ICA-105665 Unknown 100 mg Oral

Indications